|
|
News
ApoImmune Finalist for "Best Early-Stage Vaccine Biotech" at World Vaccine Congress ViE Awards
ApoImmune, Inc., a Louisville-based
biotechnology company developing vaccines and immunotherapies was selected as a
finalist for "Best Early-Stage Vaccine Biotechnology Company" at the recently held
World Vaccine Congress in Washington, DC. The Vaccine Industry Excellence (ViE)
Awards are an integral part of the annual World Vaccine Congress and recognize the
outstanding achievements of vaccine practitioners and stakeholders across the global
industry. These awards have been created to honor and generate recognition of the
efforts, accomplishments, and positive contributions of companies and individuals in the
vaccine industry.
Now in its 9th year, the World Vaccine Congress remains the industry’s definitive
vaccine industry event for major vaccine players. Officially the longest-running and
largest vaccine industry event in North America, the World Vaccine Congress delivers a
forum where the ever-changing dynamics of the vaccine industry are discussed and acted
upon by the industry’s most senior figures.
"Almost 400 attendees from more than 200 companies from around the world attended
the World Vaccine Congress this year and we were honored to be selected as a finalist for
‘Best Early-Stage Vaccine Biotech,’" said Steven T. Downey, President and CEO of
ApoImmune, Inc. "Being chosen as a finalist for this prominent award demonstrates that
the industry recognizes the innovative nature of our technology and its strong commercial
potential. We believe that ApoImmune’s broad vaccine platform technology and the
commercial potential it holds to treat unmet clinical needs in cancer and infectious
diseases is now being recognized around the world. We are looking forward to furthering
our work and reputation, and hope to accelerate the transition of our technology into the
marketplace."
"The recognition of ApoImmune’s promising technology by world leaders in the industry
is the latest evidence that Louisville’s life sciences industry has arrived on the
international scene," said Steve Gailar, CEO of MetaCyte Business Lab, a health sciences
incubator that provides services to ApoImmune. "We are proud to be working with such
an excellent team."
|
|
